PD GENEration and Barriers to Parkinson Diagnosis - Part 1 -

Amplifying the Patient Journey Image

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Special Report: 2025 Neurology FDA Drug & Device Approvals & Clearances
Special Report: 2025 Neurology FDA Drug & Device Approvals & Clearances
Alzheimer Disease & Dementias
Special Report: 2025 Neurology FDA Drug & Device Approvals & Clearances
INTREPID (A randomized, double-blind, sham-controlled study of subthalamic nucleus (STN) deep brain stimulation (DBS) for the treatment of individuals with Parkinson disease; NCT01839396)
INTREPID (A randomized, double-blind, sham-controlled study of subthalamic nucleus (STN) deep brain stimulation (DBS) for the treatment of individuals with Parkinson disease; NCT01839396)
Movement Disorders
INTREPID (A randomized, double-blind, sham-controlled study of subthalamic nucleus (STN) deep brain stimulation (DBS) for the treatment of individuals with Parkinson disease; NCT01839396)
Jerrold L. Vitek, MD, PhD
Jerrold L. Vitek, MD, PhD
Movement Disorders Moment: Sleep-Related Movement Disorders—A Review
Movement Disorders Moment: Sleep-Related Movement Disorders—A Review
Movement Disorders
Movement Disorders Moment: Sleep-Related Movement Disorders—A Review
Morris Chang, MD
Morris Chang, MD
Microplastics and "Negative Neuroplasticity": An Emerging Topic in Clinical Neurology
Microplastics and "Negative Neuroplasticity": An Emerging Topic in Clinical Neurology
Practice Management
Microplastics and "Negative Neuroplasticity": An Emerging Topic in Clinical Neurology
Keshav Shah, MBBS; David Davis, PhD
Keshav Shah, MBBS; David Davis, PhD